Bio Farma Targets Indovac Vaccine To Get BPOM Permit Next Month

Illustration (Photo: Doc. Antara)

JAKARTA - President Director of Bio Farma Honesti Basyir set a target for the COVID-19 vaccine for BUMN or Indovac to obtain an emergency use authorization (EUA) from Food and Drugs Supervisory Agency (BPOM) in early mid-September.

"God willing, hopefully in early or mid-September we will soon get the EUA from BPOM. So that later Indonesia will be truly independent and we can produce it ourselves," Honesti said at the Ngopi Bareng BUMN event broadcast on Instagram @kementerianbumn, Monday, August 22.

Furthermore, Honesti said, the COVID-19 vaccine has also been carried out in clinical trials involving 3.000 volunteers and the results are promising.

"We are almost done. Again, the results are registered at BPOM, thank God, based on the data we collected during clinical trials," he said.

The development of this vaccine, said Honesti, is a manifestation of the commitment of state-owned pharmaceutical companies in strengthening the resilience of the health sector in the country.

He said that the Indovac vaccine was developed in collaboration with the University in the United States, namely Baylor College of Medicine (BMC) with a recombinant-based vaccine.

The name Indovac for the vaccine produced by BUMN, said Honesti, was given by President Joko Widodo (Jokowi). Indovac is Singkawang from Indonesia vaccine.

"We are developing a COVID vaccine. While the name is BUMN vaccine. But a month ago the President was given a name. It's called Indovac, Indonesia vaccine," he explained.